![]() |
Sung Hee Choi Seoul National University, Korea |
SS
Why do we need an advanced DPP4-inhibitor?
![]() |
![]() |
Jun Takeda Gifu University, Japan | BS1 Postprandial hyperglycemia and incretin-based combination therapy in type 2 diabetes |
![]() |
Bong-Soo Cha Yonsei University, Korea | BS2 The effect of Lobeglitazone, a novel insulin sensitizer, on blood glucose and fat distribution from animal study to human study |
![]() |
Kyu Yeon Hur Sungkyunkwan University, Korea | BS3 Update on SGLT2 inhibitors in the management of diabetes: efficacy and safety and beyond |
![]() |
Sung Hee Choi Seoul National University, Korea | BS4 The role of sitagliptin in the treatment of type 2 diabetes patients with cardiovascular disease |
![]() |
W David Strain University of Exeter Medical School, UK | LS1 Tackling clinical inertia: is there Time2DoMore? |
![]() |
Chong Hwa Kim Sejong General Hospital, Korea | LS2 From burning to sleep through the diabetic neuropathic pain |
![]() |
Soon Jib Yoo The Catholic University of Korea, Korea | LS3 Insulin degludec: where do we begin |
![]() |
Mathijs Bunck Eli Lilly, Netherlands | LS4 A decade GLP-1RA: from 1.0 towards 2.0 |
![]() |
Jang Won Son The Catholic University of Korea, Korea | LS5 Real world data and the relationship to randomized clinical trials: a review of the evidence for sitagliptin |
![]() |
Michael Hunter Cummings Portsmouth University, UK | LS6 New approaches to lowering blood glucose: beyond glucose control |
![]() |
Eun Jung Rhee Sungkyunkwan University, Korea | LS7 Gemigliptin: simple but powerful treatment option for T2DM with renal impairment |